Core Viewpoint - The company, Cloudbreak USA, a wholly-owned subsidiary of Bolekang Vision Cloud-B (02592.HK), is scheduled to hold a crucial meeting with the U.S. Food and Drug Administration (FDA) on December 10, 2025, regarding the Phase 2 clinical trial of its candidate drug CBT-004, which is a potential first-in-class ophthalmic medication targeting specific receptors for the treatment of vascularized eyelid lesions [1] Group 1 - The stock of Bolekang Vision Cloud-B has increased by 9.75%, reaching HKD 8.78 [1] - The Phase 2 clinical trial meeting is a significant milestone in the development process of CBT-004, focusing on the potential requirements for a Phase 3 clinical trial and new drug application [1] - CBT-004 is designed as a multi-kinase inhibitor targeting vascular endothelial growth factor receptors and platelet-derived growth factor receptors [1]
拨康视云-B(02592.HK)涨超9% 将于美国就CBT-004举行第2期临床试验后会议